Macrocure Ltd. Provides Corporate Update and Reports Fourth

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Macrocure Ltd. Provides Corporate Update and Reports Fourth Quarter and Full Year 2014 Financial Results

—Company announces anticipated timeline for DFU Phase III clinical trial results—

—Company accelerates timelines for VLU Phase III clinical trial results—

—Conference call and webcast scheduled for March 18, 2015 at 9:00 am Eastern Time—

PETACH TIKVA, Israel, March 17, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. ("Macrocure" or "the Company") (Nasdaq: MCUR ), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2014.

Recent Highlights:

  • Data from the Company's ongoing pivotal Phase III, randomized, double-blind, sham controlled clinical trial in Diabetic Foot Ulcer (DFU) is expected in October 2015. This timing is in line with the previously disclosed milestone of reporting clinical trial results in the second half of 2015.
  • Due to strong recruitment rates from its ongoing Venous Leg Ulcer (VLU), pivotal, Phase III, randomized, double-blind, placebo controlled clinical trial, the Company intends to accelerate timelines and report full clinical trial results in the first half of 2016 versus the second half of 2016.
  • Results from the Company's Mechanism of Action (MOA) study presented in February 2015 demonstrated the presence of 55 cytokines and growth factors and a significant up-regulation and amplification, by 2 to 100 fold from the baseline, of these biochemical factors in the Company's lead product candidate, CureXcell; the study is the first of its kind in the Wound Care space.
  • The MOA study suggests that the Company's science and technology have additional clinical applications that present an opportunity to expand the product pipeline to additional indications outside of wound care.
  • The Company intends to present two clinical abstracts at the upcoming Symposium for Advanced Wound Care (SAWC) in April in San Antonio, Texas.
  • Total cash position as of December 31, 2014 is $47.4 million; cash expected to be used for ongoing operating activities in 2015 is $21-$25 million.

Management Commentary

"We set far-reaching business objectives in 2014. We are proud of our accomplishments, including the on-time achievement of each of our milestones, which most notably includes consummating our Initial Public Offering, completing and initiating patient recruitment in our DFU and VLU trial, respectively, and commencing and completing our Mechanism of Action study," stated Nissim Mashiach, President and Chief Executive Officer of Macrocure.

"We reaffirm that 2015 is an important year for Macrocure. We are on schedule to report DFU clinical trial data in an expeditious manner and we are excited to report sooner-than-expected timelines in our VLU trial. To these ends, in January 2015, we successfully completed the sixth and final meeting with the Data Safety Monitoring Board for our ongoing pivotal phase III DFU study. As with prior meetings, we were advised to continue the clinical study with no modifications after receiving confirmation that no safety concerns have been observed throughout the duration of the study. Furthermore, in December 2014, we successfully completed the first DSMB meeting for the ongoing pivotal phase III VLU study. The DSMB recommended the study continue with no modifications. As a result of the accelerated timeline of our VLU study pursuant to which we intend to report full clinical trial results in the first half of 2016 versus the second half of 2016, we will not report interim trial results in second half of 2015. However, we intend to conduct a futility analysis for our VLU clinical trial, which will include quantitative results in the form of ranges of probability for success. These results are expected in the third quarter of 2015," added Mr. Mashiach.

"Finally, we continue to build our team at Macrocure with the additions of Mark Page (formerly with Credit Suisse Securities) as Chief Financial Officer and Dr. Tharuvai Ramesh, Ph.D. (formerly of Nuron Biotech, Pfizer and Wyeth) as VP Operations. These moves strengthen our resources and expertise and further positions Macrocure to realize our promise of transforming the advanced wound care space," concluded Mr. Mashiach.

Financial Results for the Fourth Quarter Ended December 31, 2014

Research and development expenses for the fourth quarter of 2014 were $5.7 million, compared with $3.0 million for the fourth quarter of 2013. This increase was primarily due to significant increases in patient recruitment and enrollment, especially in our VLU study.

General and administrative expenses for the fourth quarter of 2014 were $1.9 million, compared with $0.8 million for the fourth quarter of 2013. This increase was primarily due to increased professional expenses and other customary costs associated with being a publicly-traded company.

For the fourth quarter of 2014, the Company posted a net loss of $7.6 million, or $0.42 loss per share compared with a net loss of $3.9 million, or $0.52 loss per share, in the fourth quarter of 2013.

Financial Results for the Year-Ended December 31, 2014

Research and development expenses for the twelve months ended December 31, 2014 were $15.5 million, compared with $9.3 million for the comparable period in 2013. This increase was primarily due to the ongoing clinical development of CureXcell, including increased expenditures associated with the continued and increased patient recruitment in the DFU and VLU trials.

General and administrative expenses for the twelve months ended December 31, 2014 were $5.4 million, compared with $4.6 million for the comparable period in 2013. This increase was primarily due to expenses incurred during the IPO, increased professional expenses and other customary costs associated with being a publicly-traded company.

Finance expenses, net for the twelve months ended December 31, 2014 were $4.5 million, compared with $4.3 million for the comparable period in 2013. These items are both one-time, non-cash expenses associated with a convertible credit line made available to the Company in 2014 and a revaluation of warrants in 2013.

For the twelve months ended December 31, 2014, the Company posted a net loss of $25.5 million, or $2.15 loss per share, compared with a net loss of $18.3 million, or $2.46 loss per share, for the comparable period in 2013.

Balance Sheet Highlights and Other Items

As of December 31, 2014, cash and cash equivalents, including short-term and long-term deposits were $47.4 million, compared with $19.0 million as of December 31, 2013. This increase was due to the completion of the Company's Initial Public Offering on August 5, 2014, which resulted in the Company's receipt of approximately $46.7 million in net proceeds.

As of February 28, 2015, the Company had 16,702,225 ordinary shares outstanding. This figure excludes an additional 1,339,244 ordinary shares issuable upon exercise of warrants at an exercise price of NIS 0.01 per share that were outstanding as of that date.

Guidance

We expect cash used for ongoing operating activities in 2015 will be $21-$25 million, reflecting anticipated expenditures to complete our current phase III clinical trials in process this year. This range excludes approximately $4 million in potential capital expenditures in 2015 primarily for our new U.S. manufacturing facility; the exact timing of such capital expenditures is yet to be determined.

Expected Corporate Milestones

  • 3Q 15: Phase III futility analysis results for VLU
  • October 2015: Phase III clinical trial results for DFU
  • 1H 2016: Phase III results for VLU
  • 2H 2016: Submit BLA to the FDA

Financial Results Conference Call and Webcast

Macrocure's management will host a conference call to discuss the financial results and provide a business update on Wednesday, March 18, 2015 at 9:00 am EDT; 6:00 am PDT; 4:00 pm Israel time. Shareholders and other interested parties may participate in the call by dialing (877) 303-6496 (domestic/U.S.) or (315) 625-3080 (international) and provide Conference ID: 90068247. Alternatively, to access a live audio webcast of the call please visit the Investor Relations section of the Company's website at http://investor.macrocure.com . The audio webcast will continue to be available for 30 days.

About Macrocure Ltd.

Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers. The Company's novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body's own wound healing and regenerative components directly into the wound itself.

Macrocure's lead product candidate, CureXcell, is a unique combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. CureXcell is currently in two pivotal Phase III, double-blind clinical trials targeting a broad indication for the treatment of all types of wounds below the knee. For more information, please visit: www.macrocure.com .

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecasts, commercial results, clinical trials and regulatory authorizations. Forward-looking statements are based on Macrocure's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in regulatory approval process or additional competition in the market, including those risks discussed under the heading "Risk Factors" in Macrocure's Registration Statement on Form F-1 filed with the Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this announcement and Macrocure undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

 
Audited Condensed Interim Consolidated Statements of Financial Position as of
     
U.S. dollars in thousands As of Dec-31 As of Dec-31
  2014 2013
     
Assets    
     
Current assets    
Cash and cash equivalents 10,868 18,995
Short term deposits 35,313 --
Accounts receivable  536 569
Total current assets  46,717 19,564
     
Non-current assets    
Property and equipment, net 451 330
Intangible assets, net 276 827
Deposits 1,255 17
Total non-current assets  1,982 1,174
     
Total assets 48,699 20,738
     
Liabilities and Shareholders' Equity     
     
Current liabilities    
Trade and other payables 2,488 1,971
Total liabilities  2,488 1,971
     
Shareholders' equity    
Ordinary shares of NIS 0.01 par value 45 20
Series A preferred shares of NIS 0.01 par value -- *
Share premium 95,941 48,158
Capital reserve 6,167 5,117
Warrants held by shareholders 12,256 8,219
Accumulated deficit (68,198) (42,747)
Total shareholders' equity  46,211 18,767
     
Total liabilities and shareholders' equity  48,699 20,738
     
*  Represents an amount lower than $1.
 
 
Audited Condensed Interim Consolidated Statements of Loss
         
  Twelve months Three months
  ended ended
U.S. dollars in thousands December 31, December 31,
  2014 2013 2014 2013
         
Research and development expenses, net 15,542 9,303 5,679 3,020
General and administrative expenses 5,374 4,567 1,862 835
Operating Loss (20,916) (13,870) (7,541) (3,855)
         
Finance expenses, net (4,504) (4,305) (94) 50
         
Loss before income tax (25,420) (18,175) (7,635) (3,805)
Taxes on income (31) (149) 47 (50)
         
Loss for the period (25,451) (18,324) (7,588) (3,855)
         
Other Comprehensive Loss that will be transferred to profit or loss:        
         
Net change in fair value of available for sale financial assets (26) -- (26) --
         
Total comprehensive loss for the year (25,477) (18,324) (7,614) (3,855)
         
Loss per share - basic and diluted (in U.S. dollars) (*) (2.15) (2.46) (0.42) (0.52)
 
 
Audited Condensed Interim Consolidated Statements of Cash Flows
         
U.S. dollars in thousands
         
  Twelve months ended Three months ended
  December 31, December 31,
  2014 2013 2014 2013
         
Cash flows from operating activities:        
Loss for the period (25,451) (18,324) (7,588) (3,855)
         
Adjustments:        
Depreciation 106 89 24 25
Amortization 551 551 137 138
Financing expenses, net 4,504 4,305 94 (50)
Taxes on income 31 149 (47) 50
Share based compensation 1,663 2,648 441 216
  6,855 7,742 649 379
Changes in operating assets and liability items:        
Decrease (increase) in accounts receivable 158 118 764 124
Increase (decrease) in trade and other payables 692 440 659 (471)
  850 558 1,423 (347)
         
Income tax paid (303) -- (151) --
Interest received 32 85 18 27
         
Net cash used in operating activities (18,017) (9,939) (5,649) (3,796)
         
Cash flows from investing activities:        
Purchase of property and equipment (227) (116) (1) (46)
Decrease (Increase) in long terms deposits (1,238) 2 (1,245) 1
Investment in short term deposits (17,829) -- (10,329) --
Investment in Available for Sale financial assets (17,563) -- (17,563) --
Repayment of available for sale financial assets 53 -- 53 --
         
Net cash used in investing activities (36,804) (114) (29,085) (45)
         
Cash flows from financing activities:        
Proceeds from issuance of shares and warrants, net of issuance costs 46,689 13,750 -- --
Exercise of warrants 198 -- -- --
         
Net cash provided by financing activities 46,887 13,750 -- --
         
Net increase (decrease) in cash and cash equivalents (7,934) 3,697 (34,734) (3,841)
         
Effect of exchange rate changes on cash and cash equivalents (193) (24) (183) (13)
         
Cash and cash equivalents at beginning of the period 18,995 15,322 45,785 22,849
         
Cash and cash equivalents at end of the period 10,868 18,995 10,868 18,995

Francesca DeMartino Investor Relations & Corporate Communications +1 (310) 739-6476

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 107

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 78

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading

Top 5 Most Recently Viewed Articles

Lido Staked Ether Experiences Significant Price Fluctuations

Updated Category News Views 50

The Recent Surge in Lido Staked Ether Lido Staked Ether has recently recorded a notable price increase of 3.0% in just the last 24 hours, now trading at $2,344.75. This rise seems to go against its trend over the past week, during which time the asset experienced a slight decline of 1.0%, falling from $2,333.90. The cryptocurrency has impressive highs, having reached an...

Continue Reading
Stella Artois Showcases Friendship with Super Bowl Ad Featuring Icons

Updated Category News Views 665

Stella Artois Presents an Iconic Super Bowl LIX Ad This year, Stella Artois crafts a memorable advertisement for Super Bowl LIX, showcasing the significance of connection through everyday moments. The campaign, titled 'For Moments Worth More,' aims to highlight how the simple pleasures in life can be elevated with the right company and a refreshing Stella Artois lager....

Continue Reading
Glucotrack Appoints New VP to Bolster Regulatory Strategy

Updated Category News Views 229

Glucotrack Welcomes Ted Williams as VP of Regulatory Affairs Glucotrack, Inc. is proud to announce the addition of Ted Williams as the new Vice President of Regulatory Affairs. This strategic move marks a significant step for the company as it continues to innovate and develop solutions for individuals managing diabetes. With nearly 25 years in the industry, Williams...

Continue Reading
Landstar System's Special Dividend Announcement for Shareholders

Updated Category News Views 156

Landstar System, Inc. Declares Special Cash Dividend Recently, Landstar System, Inc. (NASDAQ: LSTR) made headlines with an exciting announcement: a special one-time cash dividend of $2.00 per share. This decision, declared by the Board of Directors on a recent date, reflects the company's robust financial health and commitment to returning value to its shareholders....

Continue Reading
Market Insights: Economic Indicators and Trends to Watch

Updated Category News Views 276

Key Economic Indicators to Watch As we navigate through the current trading landscape, several economic indicators and events are set to shape the market narrative. Understanding these factors is crucial for informed trading decisions. Upcoming Economic Releases Starting the week, we have some pivotal economic releases lined up: Monday's Highlights The week begins with...

Continue Reading